Related Experiment Video
Updated: Aug 29, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
Hong-Hong Zhang1,2, Xiao-Jing Du1, Mei-Ling Deng1
1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Apatinib shows promise as a salvage therapy for recurrent glioblastoma multiforme (GBM), demonstrating a 52.6% objective response rate. This treatment was generally well-tolerated, offering a manageable toxicity profile for patients with this challenging brain cancer.
Area of Science:
- Neuro-oncology
- Medical Oncology
- Clinical Pharmacology
Background:
- Recurrent/progressive glioblastoma multiforme (GBM) presents a significant therapeutic challenge with limited established treatment options.
- Developing effective salvage strategies is crucial for improving outcomes in GBM patients.
Purpose of the Study:
- To evaluate the efficacy and safety of apatinib as a treatment for patients with recurrent or progressive glioblastoma multiforme.
- To assess objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
Main Methods:
- Retrospective analysis of 19 recurrent/progressive GBM patients treated with apatinib from November 2015 to December 2019.
- Assessment of clinical data including ORR, DCR, PFS, OS, and treatment-related adverse events (AEs).
Main Results:
- Apatinib achieved an ORR of 52.6% and a DCR of 73.7% in the study cohort.
- Median progression-free survival (PFS) was 5.1 months, and median overall survival (OS) was 10.4 months.
- Common grade 3/4 adverse events included hand-foot syndrome (36.8%) and hypertension (21.1%), with generally manageable toxicity.
Conclusions:
- Apatinib represents a viable salvage treatment option for patients with recurrent/progressive GBM.
- The observed efficacy and manageable toxicity profile suggest apatinib's potential role in managing recurrent GBM.
